Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions

Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions

Cytomegalovirus (CMV) reactivation in patients with autoimmune bullous disease (AIBD) or severe drug eruption treated with immunosuppressive therapy was traditionally thought to be merely an epiphenomenon of the underlying immunosuppression. However, a detailed review of the clinical course of these...

Full description

Bibliographic Details
Main Authors: Yumi Aoyama, Seiko Sugiyama, Takenobu Yamamoto
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceuticals
Subjects:
cytomegalovirus reactivation
anti-CMV therapy
immune reconstitution inflammatory syndrome
dipeptidyl peptidase 4 inhibitor-associated bullous pemphigoid
autoimmune bullous disease
Online Access:https://www.mdpi.com/1424-8247/15/7/797

Similar Items

Similar Items